Cayuga Biotech Raises $8 Million to Advance Innovative Hemorrhage Therapies
Cayuga Biotech, a clinical-stage biotechnology company focused on developing innovative hemostatic therapies to address life-threatening hemorrhage, has secured substantial funding from a diverse group of investors to accelerate its therapeutic programs and support advancement toward clinical milestones. The company’s most recent financing activity includes an $8 million seed funding round, marking a significant step forward in its efforts to bring novel treatments to patients suffering from uncontrolled bleeding.
The seed round was led by Wharton Alumni Angels, which contributed approximately $5 million of the total funding. Participation in the round came from a broad mix of early-stage and specialized investors, reflecting confidence in Cayuga’s technology and clinical strategy. Among the participating investors were Gopher Angels, a Minnesota-based angel network that invests in healthcare and technology startups; Mass Medical Angels, a Boston-area group focused on medical innovation; New York Ventures, the venture capital arm of Empire State Development; NuFund Venture Group; Purchase Capital; SideCar Ventures; SOSV, a global venture capital firm; TBD Angels; and Walnut Ventures. These investors collectively backed Cayuga’s mission to advance its lead therapeutic candidate and expand its pipeline targeting acute and inherited bleeding disorders.
In addition to private capital, Cayuga Biotech received a $3 million award from the Defense Health Agency (DHA) Research & Engineering Division through the Medical Technology Enterprise Consortium (MTEC). This non-dilutive funding provides strategic support for advancing Cayuga’s lead program, CAY001, into clinical studies, with the goal of generating early human proof-of-concept data in 2026.
Cayuga’s therapeutic focus centers on CAY001, a first-in-class synthetic polyphosphate-silica nanoparticle (polyP-SNP) complex designed to accelerate the body’s natural clotting process, particularly in contexts where conventional hemostatic agents fall short, such as non-compressible bleeding. The company’s pipeline also includes CAY002, a discovery-stage program targeting inherited bleeding disorders, along with additional early-stage programs that span the healing continuum.
The latest funding will be deployed to support the advancement of CAY001 into the clinic and expand Cayuga’s broader R&D efforts. With clinical translation as a priority, the company aims to leverage its recent financing to strengthen operational capabilities, accelerate regulatory progress, and bring its innovative treatments closer to patients.
Cayuga Biotech’s investors represent a mix of angel groups, venture firms, and institutional backers with healthcare and life-science expertise. SOSV, known for its deep commitment to early-stage bioscience companies, has backed Cayuga through multiple prior rounds, demonstrating long-standing confidence in the company’s approach. New York Ventures brings regional economic development focus through public capital investment, while groups like Mass Medical Angels and Gopher Angels offer networks and experience across medical innovation sectors. The participation of SideCar Ventures and NuFund Venture Group further underscores a broader ecosystem of support for emerging biotech ventures addressing critical unmet needs.
Cayuga’s funding trajectory reflects both the interest of early-stage investors in platform biotech companies and the strategic opportunities offered by partnerships with defense and government agencies. The combination of private and public funding is designed to provide the runway necessary for Cayuga to generate meaningful clinical data and attract future investment as it progresses toward Phase 1 studies.
Founded in 2015 and headquartered in New York, Cayuga Biotech operates with a lean team dedicated to solving fundamental challenges in hemorrhage control — a global health issue that contributes to millions of deaths annually due to trauma, surgery complications, and bleeding disorders. With enhanced financial backing, the company is positioning itself to make significant progress in a field where effective, rapid-acting solutions are urgently needed.
